logo
Twitter
Discord
Email
logo
Profound Medical Corp.

Profound Medical Corp.

NASDAQ•PROF
CEO: Dr. Arun Swarup Menawat MBA, Ph.D.
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2019-10-29
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Contact Information
2400 Skymark Avenue, Unit 6, Mississauga, ON, L4W 5K5, Canada
647-476-1350
www.profoundmedical.com
Market Cap
$240.41M
P/E (TTM)
-6.0
33.6
Dividend Yield
--
52W High
$8.95
52W Low
$3.76
52W Range
81%
Rank60Top 89.2%
2.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$5.23M+84.69%
4-Quarter Trend

EPS

$0.26-168.42%
4-Quarter Trend

FCF

-$9.48M+38.88%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Growth Strong Nine-month revenue reached $10.12M, increasing 56% driven by US capital sales and recurring revenue growth.
Gross Profit Surges Three-month Gross Profit $3.93M, surging 120%; Gross Margin improved substantially to 74% from 63%.
Capital Sales Driver Nine-month Capital Equipment revenue $2.69M, a major driver, compared to $952K in the prior nine months.
R&D Investment Ramps Nine-month R&D expenses reached $16.32M, increasing 33% due to CAPTAIN trial enrollment and headcount growth.

Risk Factors

Liquidity Concerns Exist Cash balance $24.83M insufficient for next twelve months operations, raising substantial going concern uncertainty.
Debt Covenant Breach Risk Projected violation of CIBC Credit Agreement liquidity covenant by June 30, 2026, risking immediate debt acceleration.
Operating Costs Rising Nine-month operating expenses climbed 43% to $41.29M, driven by R&D and SG&A expansion costs.
Net Loss Widening Nine-month Net Loss attributed to shareholders $34.40M, representing a 50% increase in period loss.

Outlook

Financing Strategy Underway Management actively pursuing equity, debt, or strategic alliances to secure funding for operations beyond next year.
Internal Control Remediation Internal control remediation for revenue recognition ongoing; expected completion of management's plan during fiscal year 2025.
Product Adoption Focus Continued substantial investment in R&D to support reimbursement efforts and further product development initiatives.
Future Compliance Dependent Future CIBC covenant compliance hinges on achieving specific revenue targets, EBITDA levels, and unrestricted cash balances.

Peer Comparison

Revenue (TTM)

Owlet, Inc.OWLT
$99.66M
+26.8%
Sight Sciences, Inc.SGHT
$76.05M
-4.4%
AVITA Medical, Inc.RCEL
$72.40M
+20.6%

Gross Margin (Latest Quarter)

MaxCyte, Inc.MXCT
92.4%
+16.1pp
Sight Sciences, Inc.SGHT
86.4%
+2.5pp
TriSalus Life Sciences, Inc.TLSI
83.5%
-2.8pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
FBRX$399.61M-11.0-75.6%0.0%
SGHT$318.29M-6.8-61.6%35.0%
PROF$240.41M-6.0-86.8%0.7%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
12.2%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 5, 2026
|
EPS:-$0.28
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 13, 2025|
    Revenue: $5.23M+84.7%
    |
    EPS: $0.26-168.4%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 14, 2025|
    Revenue: $2.21M-1.0%
    |
    EPS: $-0.52+85.7%
    Meet

  • Form 40-F - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 7, 2024|
    Revenue: $7.20M+7.8%
    |
    EPS: $-1.35+2.2%
    Beat

  • Form 40-F - FY 2022

    Period End: Dec 31, 2022|Filed: Mar 7, 2023|
    Revenue: $6.68M-2.8%
    |
    EPS: $-1.38+8.0%
    Meet

  • Form 40-F - FY 2021

    Period End: Dec 31, 2021|Filed: Mar 3, 2022|
    Revenue: $6.87M-5.9%
    |
    EPS: $-1.50-20.0%
    Meet

  • Form 40-F - FY 2020

    Period End: Dec 31, 2020|Filed: Mar 2, 2021|
    Revenue: $7.30M+72.6%
    |
    EPS: $-1.25+10.1%
    Beat